Gautam Jayram News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Gautam jayram. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Gautam Jayram Today - Breaking & Trending Today
Protara Therapeutics (TARA) Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Protara Therapeutics Announces Positive Three-Month Data From TARA-002 Clinical Program In NMIBC menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Gautam Jayram, MD, discusses current standards of care in the bladder cancer treatment arena, novel therapies under investigation in clinical trials that may expand the arsenal of available treatment strategies, and emphasizes the importance of implementing bladder cancer programs. ....
Gautam Jayram, MD, discusses the current indications for immunotherapy agents in the bladder cancer treatment paradigm, as well as immune-related adverse effects to be aware of when treating patients who are receiving these therapies. ....
Press release content from Accesswire. The AP news staff was not involved in its creation. Theralase Launches Second Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study January 20, 2021 GMT TORONTO, ON / ACCESSWIRE / January 20, 2021 / Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses announced today that Urology Associates P.C. (“UA”) has received site Institutional Review Board (“IRB”) approval to commence a pivotal phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) Clinical Study to enroll and treat patients with Bacillus Calmette Guerin(“BCG”)-Unresponsive Carcinoma In-Situ (“CIS”) or are intolerant to BCG Therapy (“Study II”). ....